US sends Ebola drug to DRC for outbreak trials (opens original article in a new tab)

The US has sent an experimental Ebola antibody drug to the DRC for clinical trials as part of efforts to combat the ongoing outbreak, which has caused over 1,000 cases and 250 deaths. The drug, developed by Mapp Biopharmaceutical, will be tested alongside Gilead's antivirals, while vaccine trials remain further away.

• US provides experimental Ebola drug to DRC for clinical trials
• Mapp Biopharmaceutical's MBP134 will be tested on its own and with Gilead's remdesivir
• No approved vaccines or treatments exist for Bundibugyo strain of Ebola
• Trials face challenges in conflict-affected regions with disrupted supply chains